A Case of E138K Cabotegravir/Rilpivirine Resistance: Challenges and Concerns When Persons Living With HIV Relocate

Abstract

Get full access to this article

View all access options for this article.

References

Overton

Richmond

Rizzardini

, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study. Clin Infect Dis. 2023;76:1646-1654. doi:10.1093/cid/ciad020

Orkin

Schapiro

Perno

, et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis. 2023;77:1423-1431. doi:10.1093/cid/ciad370

Van Welzen

Van Lelyveld

SFL

Ter Beest

, et al. Virologic failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis. Clin Infect Dis. 2024:11:ciae016. doi:10.1093/cid/ciae016

Shankaran

Hernanadez-Guarin

Jhobalia

Sha

Aziz

Virologic failure with cabotegravir-rilpivirine injections: a single-site experience. Conference on Retroviruses and Opportunistic Infections 2024; Poster 686; March 3-6, 2024; Denver, CO.

Masich

Gomes

Higginson

, et al. HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program. AIDS. 2023;37:1641-1642. doi:10.1097/QAD.0000000000003590

Nachega

Scarsi

Gandhi

, et al. Long-acting antiretrovirals and HIV treatment. Lancet HIV. 2023;10:e332-e342. doi:10.1016/S2352-3018(23)00051-6